Lexology November 14, 2024
Morgan Lewis & Bockius LLP

By Jacqueline Berman, Michele Buenafe and Kathleen Sanzo (November 14, 2024, 6:41 PM EST)

The reelection of former President Donald Trump, coupled with Republicans gaining the Senate majority and poised to gain the House majority, has prompted many in the life sciences industry to question how this political shift may affect the regulation of drugs, devices and other life sciences products by the U.S. Food and Drug Administraiton and related regulators.

While Trump has not yet articulated specific policy priorities with respect to the life sciences industry, what is clear is that the sector is positioned to see significant changes. We describe below key areas to watch as the new Trump-Vance administration takes shape.

Jacqueline Berman

New Agency Heads and...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Pharma, Pharma / Biotech, Regulations
Related Articles:
CVS Plans Chain of Smaller-Footprint Pharmacy-Focused Stores
As Walgreens Preps For New Owner, CVS Health Tries Smaller Drugstores
AACR Precision Medicine 2025: AACR Past-President Elaine R. Mardis, PhD, Discusses Highlights of the Meeting for Pharmacists
Anna Greka: Molecular Sleuthing for Rare Diseases
Gene Therapy in an Implant: Neurotech Lands First FDA Approval in Rare Vision Disorder

Share This Article